September 30th 2024
Gil Yosipovitch, MD, reviews differences including lesion appearance, cytokine pathways, treatment options, and more.
September 25th 2024
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Diving into Atopic Dermatitis and its Rapidly Expanding Pipeline
January 15th 2022In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.
FDA approves Tralokinumab-Idrm for AD
December 28th 2021Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.